R&D Pipeline
Nektar Therapeutics has a deep and diverse portfolio of investigational medicines in different stages of clinical development. We are focused on using new chemistry approaches to make better medicines to treat cancer and auto-immune disease.
Nektar Therapeutics also has a number of strategic partnerships ranging from joint discovery and co-development to licensing and royalty arrangements with numerous companies.
Bempegaldesleukin (NKTR-214) in combination with OPDIVO® (nivolumab)
Indication: Metastatic Melanoma
Partner
Bempegaldesleukin in combination with OPDIVO® (nivolumab)
Indication: Renal Cell Carcinoma
Partner
Bempegaldesleukin in combination with OPDIVO® (nivolumab)
Indication: Muscle-invasive Bladder Cancer
Partner
Bempegaldesleukin in combination with OPDIVO® (nivolumab)
Indication: Adjuvant Melanoma
Partner
Bempegaldesleukin in combination with OPDIVO® (nivolumab)
Indication: Urothelial Cancer*
Partner
Dapirolizumab Pegol (Anti-CD40L)
Indication: Systemic lupus erythematosus (SLE)
Partner
In partnership with
Systemic lupus erythematosus (SLE) is a chronic inflammatory disease that occurs when the body's own immune system mistakenly attacks healthy tissue in skin, joints, kidneys, the brain and other organs. It is a difficult disease to diagnose because it resembles several other conditions.
CD40L is a protein in B and T cells, which helps regulate the immune system. Dapirolizumab pegol (Anti-CD40L) is an antibody that blocks CD40L, potentially lessening disease activity in SLE patients. Dapirolizumab pegol is being developed by Biogen and UCB, Inc. in a Phase 2 clinical trial to evaluate the efficacy and safety of dapirolizumab pegol in patients with moderately to severely active systemic lupus erythematosus. For more information about this study, visit clinicaltrials.gov.
NKTR-255 monotherapy and in Combination with Rituxan© (rituximab) or Darzalex Faspro© (daratumumab)
INDICATION: Non-Hodgkin’s Lymphoma and Multiple Myeloma
Discovered and wholly owned by Nektar
Unpartnered
More InfoLess InfoNKTR-255 is a memory T cell stimulating cytokine designed to engage the IL-15 pathway to enhance and sustain long-term T cell memory response to treat cancer.
NKTR-255 in combination with Erbitux© (cetuximab) in Solid Tumors
INDICATION: Head and Neck Cancer and Colorectal Cancer
Discovered and wholly owned by Nektar
Unpartnered
More InfoBempegaldesleukin in combination with VB10.NEO
Indication: Squamous Cell Carcinoma of the Head and Neck
In clinical collaboration with
Bempegaldesleukin in combination with KEYTRUDA® (pembrolizumab)
Indication: Non-Small Cell Lung Cancer
Discovered and wholly owned by Nektar
Unpartnered
More InfoNKTR-262 in combination with bempegaldesleukin
INDICATION: Locally Advanced or Metastatic Solid Tumor Malignancies
Discovered and wholly owned by Nektar
Unpartnered
More Info*Planned registrational study
